美股市場個股詳情

ARWR Arrowhead Pharmaceuticals

添加自選

24.130
+0.960+4.14%

收盤價 05/02 16:00 (美東)

24.530
+0.400+1.66%

盤前 09:04 (美東)

29.90億總市值-8711市盈率TTM

Arrowhead Pharmaceuticals股票討論區

登錄發表評論

stockhub

04/08 00:23

Hope price action is consistent with result

Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia
$Arrowhead Pharmaceuticals(ARWR.US)$

投資圓桌會

Tonyco

04/07 11:01

$Arrowhead Pharmaceuticals(ARWR.US)$
Insiderd selling shares and financials dont look good. Im guessing they dont have anything in the pipeline?

Moomoo AI

03/08 19:54

The company's poor performance and the CEO's high pay, despite falling earnings and shareholder value, may upset shareholders. The upcoming AGM on March 14th is a chance for shareholders to hold the board and management accountable.

We Think Shareholders May Want To Consider A Review Of Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

zulia3003

03/08 01:34

$Arrowhead Pharmaceuticals(ARWR.US)$ why drop today?

AuthPresidentColor8c

03/02 00:33

$Arrowhead Pharmaceuticals(ARWR.US)$ such a odd spot here

Yemaozi

02/29 02:30

$Arrowhead Pharmaceuticals(ARWR.US)$log Chatter表示：“關注情況的人聽說有人猜測Arrowhead Pharmicals最近拒絕了每股45美元左右的指示性方針。“; 股價飆升

已翻譯

ApextradezCOM

02/26 05:54

PH.2 Results + ER Win =🚀

$塞德斯醫療(CLDX.US)$
$Arrowhead Pharmaceuticals(ARWR.US)$ - Alpha Early Alert 🚨 H&S 📈🎯🚀🥇 (45.00) is on the Table 🫵🏻💪🏻🥇 Find the Apex and win!

Moomoo AI

01/04 20:44

The company's P/S ratio is high in contrast to its lower projected growth, a divergence that could bring risk to shareholders and potential investors. The current P/S ratio might not sustain due to predicted future revenues.

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 36% But Its Business Is Yet to Catch Up

Moomoo AI

2023/12/14 23:54

High level of risk for Arrowhead Pharmaceuticals with negative EBIT and a dip in free cash flow. The company burnt US$331m, reported a US$205m loss raising capital raising flags. Investors monitor balance sheet and warning signs needed.

Health Check: How Prudently Does Arrowhead Pharmaceuticals (NASDAQ:ARWR) Use Debt?

Moomoo AI

2023/11/23 18:30

Javier San Martin's insider sale at current price level is not a major concern, nor a positive sign. The lack of insider buying over the past year and mediocre level of insider ownership warrant caution in purchasing its stock.

Arrowhead Pharmaceuticals Chief Medical Officer Javier San Martin Sells 36% Of Holding

暫無評論

分析

分析師評級

暫無數據

目標價預測

暫無數據

熱議

美股

綜合熱度